Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 2/20 | 0.39 |
| ▸ | PYGL | P06737 | 2/20 | 0.38 |
| ▸ | PYGM | P11217 | 2/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989682 | 0.92 | SCN9A (0.49) | RIPK1SCN9AXIAPPYGLPYGM | |
| SCHEMBL1740427 | 0.88 | RIPK1 (0.44) | RIPK1SCN9APYGLPYGMCCKBR | |
| SCHEMBL9988825 | 0.82 | RIPK1 (0.41) | RIPK1SCN9APYGLPYGM | |
| SCHEMBL9990639 | 0.82 | RIPK1 (0.40) | RIPK1SCN9APYGLPYGM | |
| SCHEMBL4191956 | 0.81 | RIPK1 (0.60) | RIPK1SCN9AXIAPPYGLPYGM | |
| SCHEMBL3915586 | 0.81 | RIPK1 (0.60) | RIPK1SCN9AXIAPPYGLPYGM | |
| SCHEMBL9988922 | 0.81 | RIPK1 (0.48) | RIPK1PYGLPYGMPOLBCCKBR | |
| SCHEMBL9989693 | 0.79 | SCN9A (0.39) | RIPK1SCN9APYGLPYGMCCKBR | |
| SCHEMBL9990649 | 0.79 | RIPK1 (0.39) | RIPK1SCN9APYGLPYGMCCKBR | |
| SCHEMBL9990232 | 0.78 | RIPK1 (0.52) | RIPK1SCN9AXIAPPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319396-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | MSD K.K. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319396-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | DGAT1, DGAT2, GRIN1 | RIPK1 3797/4885SCN9A 1526/4885XIAP 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.